TY - JOUR
T1 - Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer
T2 - A brief report
AU - Desai, Aakash
AU - Rakshit, Sagar
AU - Bansal, Radhika
AU - Ashara, Yash
AU - Potter, Ashley
AU - Manochakian, Rami
AU - Lou, Yanyan
AU - Zhao, Yujie
AU - Ernani, Vinicius
AU - Savvides, Panos
AU - Schwecke, Anna
AU - Moffett, Nicole
AU - Hocum, Craig
AU - Leventakos, Konstantinos
AU - Adjei, Alex
AU - Marks, Randolph
AU - Molina, Julian
AU - Mansfield, Aaron S.
AU - Chen, Zong Ming
AU - Dimou, Anastasios
N1 - Publisher Copyright:
© 2023
PY - 2023/1
Y1 - 2023/1
N2 - Introduction: We evaluated the risk factors and outcomes for patients who experienced hepatotoxicity after use of sotorasib in KRAS G12C mutated NSCLC. Methods: Retrospective review of medical records of patients with KRAS G12C mutated NSCLC who received sotorasib between May 28th, 2021, and December 31st, 2021 across all Mayo Clinic sites, with follow up until December 31st, 2022. Results: Thirty-one patients received sotorasib as standard of care treatment. Grade 3 or higher hepatoxicity was seen in 32% (10/31) patients presenting at a median of 51 days (range, 27–123) of sotorasib initiation. Baseline demographics were comparable between patients with and without ≥grade 3 hepatotoxicity, except for presence of CNS metastases and time from prior immune checkpoint inhibitor (ICI) treatment. Improvement in liver tests was observed in all patients after stopping sotorasib, and it was restarted at a lower dose in 8 patients. Despite dose reduction, hepatotoxicity requiring sotorasib discontinuation occurred in 2 patients. Twenty-eight of 31 patients had received prior ICI. Median time from prior ICI therapy was 69 days (range, 4–542). Rates of ≥grade 3 hepatoxicity were 75% (3/4), 64% (7/11) and 0% (0/13) for patients who received ICI within 30 days, 31–90 days and >90 days. None of the 3 patients without prior ICI exposure developed hepatoxicity. The median PFS and OS were 3.9 months and 9.9 months respectively. Conclusion: One-third of patients developed grade 3 or higher sotorasib induced hepatotoxicity. Risk of hepatotoxicity was higher in patients who received sotorasib within 90 days of ICI treatment.
AB - Introduction: We evaluated the risk factors and outcomes for patients who experienced hepatotoxicity after use of sotorasib in KRAS G12C mutated NSCLC. Methods: Retrospective review of medical records of patients with KRAS G12C mutated NSCLC who received sotorasib between May 28th, 2021, and December 31st, 2021 across all Mayo Clinic sites, with follow up until December 31st, 2022. Results: Thirty-one patients received sotorasib as standard of care treatment. Grade 3 or higher hepatoxicity was seen in 32% (10/31) patients presenting at a median of 51 days (range, 27–123) of sotorasib initiation. Baseline demographics were comparable between patients with and without ≥grade 3 hepatotoxicity, except for presence of CNS metastases and time from prior immune checkpoint inhibitor (ICI) treatment. Improvement in liver tests was observed in all patients after stopping sotorasib, and it was restarted at a lower dose in 8 patients. Despite dose reduction, hepatotoxicity requiring sotorasib discontinuation occurred in 2 patients. Twenty-eight of 31 patients had received prior ICI. Median time from prior ICI therapy was 69 days (range, 4–542). Rates of ≥grade 3 hepatoxicity were 75% (3/4), 64% (7/11) and 0% (0/13) for patients who received ICI within 30 days, 31–90 days and >90 days. None of the 3 patients without prior ICI exposure developed hepatoxicity. The median PFS and OS were 3.9 months and 9.9 months respectively. Conclusion: One-third of patients developed grade 3 or higher sotorasib induced hepatotoxicity. Risk of hepatotoxicity was higher in patients who received sotorasib within 90 days of ICI treatment.
KW - Hepatotoxicity
KW - Immunotherapy
KW - Sotorasib
UR - http://www.scopus.com/inward/record.url?scp=85166618266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85166618266&partnerID=8YFLogxK
U2 - 10.1016/j.ctarc.2023.100743
DO - 10.1016/j.ctarc.2023.100743
M3 - Article
C2 - 37531736
AN - SCOPUS:85166618266
SN - 2213-0896
VL - 36
JO - Cancer Treatment and Research Communications
JF - Cancer Treatment and Research Communications
M1 - 100743
ER -